Alaska has the highest incidence of tuberculosis (TB) in the United States
with disease disproportionately affecting Alaska Native/American Indian (AN/AI)
populations and children under 14 years of age; who account for almost a third of
cases. With a case fatality rate of 8% during TB treatment and a quarter of TB cases
lacking sputum culture to enable drug resistance testing, the FreezeTB targeted next
Generation Sequencing (tNGS) diagnostic initiative was launched to develop diagnostic
genotypic drug resistance tools tailored to meet the challenges of care in Alaska, while
being translatable to other settings.
We sought to develop a rapid and cost-effective method for identifying
drug resistant mutations in Mycobacterium tuberculosis using targeted next generation
sequencing (tNGS), FREEZE TB: Fast, Reliable, Economical Evaluation tool to Zap
Endemic Tuberculosis. We designed a primer multiplex, amplification and barcoding
protocol, and sequencing workflow for nanopore sequencers, including portable
devices. We programmed an open-source (OS) software that detects mutations
associated with drug resistance recognized by the World Health Organization. One
hundred blinded M. tuberculosis sputum culture isolates from Alaska (59 resistant, 41
pan-susceptible) were selected and underwent analysis with our the FREEZETB lab
and bioinformatic workflow, then compared to phenotypic drug susceptibility testing
(pDST) using BACTEC MGIT 960.
Compared to WGS (n=79), FreezeTB tNGS and software provided the same
mutation report in 96% (n=76/79) of samples. Compared to pDST, FreezeTB had
almost perfectvery high (numerator / 79) agreement for RIF (0.904; 71/79) and EMB
(1.0; 79/79), substantial agreement for ETO (0.784) and INH (0.795), moderate
agreement for STR (0.556) and slight agreement for PZA (0.197) using Cohen’s kappa.
FreezeTB is designed to detect resistance to fluoroquinolones, bedaquiline,
pretomanid/delamanid, and linezolid;, however, no isolates had thiswere resistant to
these drugsce pattern. Using a portable nanopore sequencer, each sample was
FreezeTB provides a one-day laboratory and bioinformatic workflow for
sequencing M. tuberculosis; offering an OS software with graphical user interface and a
laboratory workflow costing under $30 per sample. Freeze TB can accurately determine
resistance for rifampin, isoniazid, streptomycin, ethambutol and ethionamide and is
designed to detect resistance in newer drugs, such as bedaquiline and pretomanid.